Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Danaher (DHR)

NYSE: DHR · Diagnostics & Research · Washington, DC

Our rating: Neutral

Neutral reaffirmed at $232.97, moderate conviction, October 26, 2026.

Breaks if: This neutral view would turn cautious if reported revenue growth goes negative in any of the next two quarterly filings, or if trailing free cash flow falls below $4.5 billion — either would signal that the re-acceleration already embedded in a 46x multiple is not arriving. Conversely, it would turn positive if top-line growth reaches 8% or above for two consecutive quarterly reports, indicating the premium is starting to earn its keep through genuine volume and pricing momentum.

Key figures

Market value$155.0B
Revenue, last 12 months$25.6B
Net income, last 12 months$4.3B
Free cash flow, last 12 months$5.7B
Price to earnings35.8×
Free cash flow yield3.7%
Dividend yield0.7%
Operating margin20.4%
Return on equity8.3%
Beta to the S&P 5000.76
Volatility, annualized30.1%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 25, 2026$6.6B8.3%$1.75$1.6B
June 26, 2026$6.3B5.5%$1.23$1.3B
March 27, 2026$6.0B3.7%$1.45$1.1B
December 31, 2025$6.8B4.6%$1.68$1.7B
September 26, 2025$6.1B4.4%$1.27$1.4B
June 27, 2025$5.9B3.4%$0.77$1.1B
March 28, 2025$5.7B−0.9%$1.32$1.1B
December 31, 2024$6.5B2.1%$1.49$1.5B

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

20 ledger entries and 29 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.